Cubist Systematic Strategies LLC acquired a new stake in shares of Vaxart, Inc. (NASDAQ:VXRT) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 60,716 shares of the biotechnology company’s stock, valued at approximately $404,000.
A number of other hedge funds also recently bought and sold shares of the stock. BlackRock Inc. increased its position in Vaxart by 26.9% during the 3rd quarter. BlackRock Inc. now owns 4,273,670 shares of the biotechnology company’s stock valued at $28,420,000 after buying an additional 907,013 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new position in Vaxart during the third quarter valued at $8,031,000. State Street Corp lifted its position in Vaxart by 16.8% during the third quarter. State Street Corp now owns 911,518 shares of the biotechnology company’s stock valued at $6,062,000 after purchasing an additional 131,096 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Vaxart by 400.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 600,942 shares of the biotechnology company’s stock valued at $3,997,000 after purchasing an additional 480,760 shares in the last quarter. Finally, Goldman Sachs Group Inc. purchased a new position in Vaxart during the second quarter valued at $3,530,000. 17.90% of the stock is owned by institutional investors.
Several equities analysts have recently commented on VXRT shares. B. Riley restated a “buy” rating and issued a $22.00 price objective on shares of Vaxart in a research report on Thursday, December 3rd. BidaskClub cut Vaxart from a “hold” rating to a “sell” rating in a research note on Friday. Finally, Zacks Investment Research cut Vaxart from a “hold” rating to a “sell” rating in a research note on Saturday, November 14th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $13.42.
Vaxart stock opened at $5.71 on Friday. The business has a fifty day moving average of $6.84 and a two-hundred day moving average of $7.33. The firm has a market cap of $625.07 million, a P/E ratio of -9.68 and a beta of -0.11. Vaxart, Inc. has a twelve month low of $0.30 and a twelve month high of $17.49.
Vaxart (NASDAQ:VXRT) last issued its quarterly earnings results on Thursday, November 12th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01. The business had revenue of $0.27 million for the quarter, compared to the consensus estimate of $1.60 million. Vaxart had a negative return on equity of 84.90% and a negative net margin of 281.50%. Research analysts anticipate that Vaxart, Inc. will post -0.35 earnings per share for the current year.
In related news, Director Wouter Latour sold 333,334 shares of the company’s stock in a transaction on Monday, November 23rd. The stock was sold at an average price of $6.32, for a total value of $2,106,670.88. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 7.30% of the stock is owned by corporate insiders.
Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which has completed Phase I clinical trials with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trials for treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine.
Recommended Story: Asset Allocation, Balancing Your Investments
Want to see what other hedge funds are holding VXRT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vaxart, Inc. (NASDAQ:VXRT).
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.